GSK plc (GLAXF)
OTCMKTS
· Delayed Price · Currency is USD
26.60
-1.93 (-6.76%)
Mar 5, 2026, 4:00 PM EST
GSK plc Revenue
In the year 2025, GSK plc had annual revenue of 32.67B GBP with 4.11% growth. GSK plc had revenue of 8.62B in the quarter ending December 31, 2025, with 6.17% growth.
Revenue
32.67B GBP
Revenue Growth
+4.11%
P/S Ratio
2.52
Revenue / Employee
475.99K GBP
Employees
68,629
Market Cap
110.68B USD
Revenue Chart
* This company reports financials in GBP.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 32.67B | 1.29B | 4.11% |
| Dec 31, 2024 | 31.38B | 1.05B | 3.46% |
| Dec 31, 2023 | 30.33B | 1.00B | 3.42% |
| Dec 31, 2022 | 29.32B | 4.63B | 18.74% |
| Dec 31, 2021 | 24.70B | 342.00M | 1.40% |
| Dec 31, 2020 | Pro | Pro | Pro |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Veradigm | 588.02M |
| Glass House Brands | 196.17M |
| Elite Pharmaceuticals | 140.12M |
| American Oncology Network | 1.76B |
| Northwest Biotherapeutics | 937.00K |
| Silence Therapeutics | 559.00K |
| Tian'an Technology Group | 2.12M |
| Vaxart | 148.20M |
GSK plc News
- 17 hours ago - Pay bonanza for blue chip bosses: Rolls-Royce chief 'Turbo' Tufan set for £24m as GSK's Walmsley scoops £15.7m - This is Money
- 1 day ago - Emma Walmsley’s pay rose almost 50% to £15.6m in final year as GSK boss - The Guardian
- 1 day ago - SCYNEXIS Posts Narrower FY25 Loss, Advances Next-Gen Antifungal Pipeline - Nasdaq
- 1 day ago - SCYNEXIS Reports Full Year 2025 Financial Results and Provides Corporate Update - Benzinga
- 1 day ago - Price Over Earnings Overview: GSK - Benzinga
- 2 days ago - GSK's Biopharma Collaborations Highlighted in AnaptysBio Spin-Off Plan - GuruFocus
- 2 days ago - GSK PLC (GSK) Shares Gap Down to $56.525 on Mar 3 - GuruFocus
- 2 days ago - GSK Completes Acquisition of Rapt Therapeutics for $2.2B - GuruFocus